126 related articles for article (PubMed ID: 11592838)
1. Antitumor activity of cationic lipid complexed with immunostimulatory DNA.
Rudginsky S; Siders W; Ingram L; Marshall J; Scheule R; Kaplan J
Mol Ther; 2001 Oct; 4(4):347-55. PubMed ID: 11592838
[TBL] [Abstract][Full Text] [Related]
2. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
[TBL] [Abstract][Full Text] [Related]
3. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously.
Dow SW; Fradkin LG; Liggitt DH; Willson AP; Heath TD; Potter TA
J Immunol; 1999 Aug; 163(3):1552-61. PubMed ID: 10415059
[TBL] [Abstract][Full Text] [Related]
4. DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells.
Yoshinaga T; Yasuda K; Ogawa Y; Nishikawa M; Takakura Y
Immunology; 2007 Mar; 120(3):295-302. PubMed ID: 17199803
[TBL] [Abstract][Full Text] [Related]
5. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
[TBL] [Abstract][Full Text] [Related]
6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
7. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
8. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
10. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs.
Yew NS; Zhao H; Wu IH; Song A; Tousignant JD; Przybylska M; Cheng SH
Mol Ther; 2000 Mar; 1(3):255-62. PubMed ID: 10933941
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of cationic lipid-DNA complexes.
Yew NS; Scheule RK
Adv Genet; 2005; 53():189-214. PubMed ID: 16240994
[TBL] [Abstract][Full Text] [Related]
12. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
13. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
14. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy.
Yew NS; Cheng SH
Expert Opin Drug Deliv; 2004 Nov; 1(1):115-25. PubMed ID: 16296724
[TBL] [Abstract][Full Text] [Related]
15. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
[TBL] [Abstract][Full Text] [Related]
16. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model.
Bertin S; Anjuere F; Gavelli A; Baque P; Soilihi BK; Brossette N; Loubat A; Pierrefite-Carle V
Int J Mol Med; 2008 Mar; 21(3):309-15. PubMed ID: 18288378
[TBL] [Abstract][Full Text] [Related]
17. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
Clark PR; Stopeck AT; Ferrari M; Parker SE; Hersh EM
Cancer Gene Ther; 2000 Jun; 7(6):853-60. PubMed ID: 10880015
[TBL] [Abstract][Full Text] [Related]
18. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
19. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
20. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex.
Jones DE; Palmer JM; Burt AD; Walker C; Robe AJ; Kirby JA
Hepatology; 2002 Sep; 36(3):679-86. PubMed ID: 12198661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
